(Q51680655)

9 April 2018

title

Inhaled steroids in COPD: when should they be used? (English)

1 reference

9 April 2018

author

Leonardo M. Fabbri

series ordinal

2

1 reference

9 April 2018

author name string

Alvar Agusti

series ordinal

1

1 reference

9 April 2018

publication date

3 November 2014

1 reference

9 April 2018

The Lancet. Respiratory medicine

published in

1 reference

9 April 2018

volume

2

1 reference

9 April 2018

issue

11

1 reference

9 April 2018

page(s)

869-871

1 reference

9 April 2018

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

Global strategy for asthma management and prevention: GINA executive summary.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

Inhaled corticosteroids in COPD: pros and cons.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

Treating COPD in the real world

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970227-9

7 January 2021

10.1016/S2213-2600(14)70227-9

Identifiers

DOI

1 reference

9 April 2018

1 reference

9 April 2018